-
公开(公告)号：US20220241333A1
公开(公告)日：2022-08-04
申请号：US17622190
申请日：2020-07-03
发明人： Sergio Quezada , Karl Peggs , Anna Sledzinska , Richard Jenner , Felipe Galvez Cancino , Maria Vila de Mucha
IPC分类号： A61K35/17 , A61P35/00 , C07K14/725 , C12N15/10
摘要： The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder in a mammalian subject, wherein the T cell has been engineered (i) to overexpress BLIMP1 and/or (ii) to knock-out or decrease expression of BCL6. Further provided is a BCL6 inhibitor for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or BCL6 inhibitor.
-
公开(公告)号：US20230158073A1
公开(公告)日：2023-05-25
申请号：US17919135
申请日：2021-04-16
发明人： Sergio Quezada , Karl Peggs , Charles Swanton , Ehsan Ghorani , James Reading , Felipe Galvez-Cancino , Despoina Karagianni
CPC分类号： A61K35/17 , A61K38/1774 , A61P35/00
摘要： The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3. Further provided are activity modulators of one or more proteins encoded by genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3 for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or inhibitor.
-
">
公开(公告)号：US20180251553A1
公开(公告)日：2018-09-06
申请号：US15758165
申请日：2016-09-12
IPC分类号： C07K16/28 , G06F19/22 , G06F19/24 , G01N33/574
CPC分类号： C07K16/2818 , C07K2317/24 , C07K2317/76 , G01N33/574 , G01N33/57411 , G16B30/00 , G16B40/00
摘要： The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.
-
公开(公告)号：US11879014B2
公开(公告)日：2024-01-23
申请号：US16494962
申请日：2018-03-03
发明人： Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
CPC分类号： C07K16/2866 , C07K14/55 , C07K16/2818 , A61K39/0011 , A61K45/06 , C07K2317/31 , C07K2317/52 , C07K2317/60 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
-
公开(公告)号：US11098121B2
公开(公告)日：2021-08-24
申请号：US15758165
申请日：2016-09-12
IPC分类号： A61K39/395 , G16B30/00 , C07K16/28 , G16B40/00 , G01N33/574
摘要： The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.
-
公开(公告)号：US20200010554A1
公开(公告)日：2020-01-09
申请号：US16494962
申请日：2018-03-03
发明人： Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
摘要： The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
-
公开(公告)号：US20230265200A1
公开(公告)日：2023-08-24
申请号：US17706028
申请日：2022-03-28
CPC分类号： C07K16/2866 , C07K16/2815 , C07K16/2812 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/505
摘要： The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyRllb (CD32b).
-
公开(公告)号：US20200000904A1
公开(公告)日：2020-01-02
申请号：US16565350
申请日：2019-09-09
IPC分类号： A61K39/00 , C12Q1/6886 , C12N5/0783 , G01N33/50 , G01N33/574
摘要： The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
-
公开(公告)号：US20200000903A1
公开(公告)日：2020-01-02
申请号：US16565342
申请日：2019-09-09
IPC分类号： A61K39/00 , C12Q1/6886 , C12N5/0783 , G01N33/50 , G01N33/574
摘要： The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
-
公开(公告)号：US20190135925A1
公开(公告)日：2019-05-09
申请号：US16091350
申请日：2017-03-17
发明人： Sergio Quezada , Karl Peggs , Fred Vargas
摘要： The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyR11b (CD32b).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.021 秒)
